NEW YORK (GenomeWeb) – Myriad Genetics reported this morning that its fiscal third quarter revenues dropped 2 percent year over year, but it still handily beat the predictions of Wall Street analysts.

For the three months ended March 31, the firm reported total revenues of $193.5 million compared to $196.9 million in its fiscal Q3 2017, beating the consensus Wall Street estimate of $188.2 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.